CYP3A7-CYP3AP1 Inhibitors

Chemical inhibitors of CYP3A7-CYP3AP1 include a range of compounds that interact with the enzyme to impede its activity. Ketoconazole is known to bind to the heme group integral to the enzyme's active site, which is crucial for the metabolic conversion of compounds. This binding effectively stops the enzymatic action, preventing CYP3A7-CYP3AP1 from catalyzing its natural reactions. Similarly, ritonavir operates by attaching itself to the active site of CYP3A7-CYP3AP1, which results in a diminished metabolic rate of the enzyme's specific substrates. Indinavir and nelfinavir employ a comparable approach; they competitively inhibit the enzyme by directly interacting with its active site, obstructing substrate access and thus, enzyme activity.

Furthermore, saquinavir's inhibition of CYP3A7-CYP3AP1 is likely analogous to its effects on CYP3A4, involving the active site binding and subsequent interference with metabolic function. Calcium channel blockers such as diltiazem and verapamil also inhibit CYP3A7-CYP3AP1 but do so by inducing a conformational change in the enzyme upon binding, which reduces its enzymatic activity. Cimetidine targets CYP3A7-CYP3AP1 and hampers its function by preventing the oxidation of molecules that the enzyme would typically metabolize. Macrolide antibiotics like erythromycin and clarithromycin form stable complexes with CYP3A7-CYP3AP1, thereby reducing the enzyme's activity. Troleandomycin acts in a fashion similar to erythromycin, by complexing with the enzyme to decrease its metabolic capability. Lastly, mibefradil, though no longer on the market, is recognized for its inhibitory action on CYP3A7-CYP3AP1, which is attributed to its binding affinity for the enzyme, consequently obstructing the processing of specific substrates. Each of these chemicals can engage with CYP3A7-CYP3AP1 in a manner that reduces its ability to fulfill its normal metabolic roles within the cell.